Amneal Pharmaceuticals, Inc. (AMRX)

USD 7.69

(-4.71%)

Operating Income Summary of Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.'s latest annual operating income in 2023 was 204.37 Million USD , down -1.01% from previous year.
Amneal Pharmaceuticals, Inc.'s latest quarterly operating income in 2024 Q1 was -10.74 Million USD , down -175.71% from previous quarter.
Amneal Pharmaceuticals, Inc. reported an annual operating income of 206.46 Million USD in 2022, down -1.32% from previous year.
Amneal Pharmaceuticals, Inc. reported an annual operating income of 209.23 Million USD in 2021, up 129.54% from previous year.
Amneal Pharmaceuticals, Inc. reported a quarterly operating income of 95.47 Million USD for 2024 Q2, up 988.42% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a quarterly operating income of 204.37 Million USD for 2023 FY, down -1.01% from previous quarter.

Annual Operating Income Chart of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Historical Annual Operating Income of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Year	Operating Income	Operating Income Growth
2023	204.37 Million USD	-1.01%
2022	206.46 Million USD	-1.32%
2021	209.23 Million USD	129.54%
2020	91.15 Million USD	166.33%
2019	-137.42 Million USD	-598.54%
2018	-19.67 Million USD	-108.03%
2017	245.1 Million USD	-13.96%
2016	284.88 Million USD	25.37%
2015	227.23 Million USD	1.92%
2014	222.94 Million USD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	-10.74 Million USD	-175.71%
2024 Q2	95.47 Million USD	988.42%
2023 FY	204.37 Million USD	-1.01%
2023 Q4	14.19 Million USD	-81.24%
2023 Q1	34.44 Million USD	-53.57%
2023 Q3	75.64 Million USD	-5.54%
2023 Q2	80.08 Million USD	132.47%
2022 Q1	23.3 Million USD	108.55%
2022 FY	206.46 Million USD	-1.32%
2022 Q4	74.19 Million USD	67.29%
2022 Q3	44.35 Million USD	122.33%
2022 Q2	-198.61 Million USD	-952.25%
2021 Q3	28.51 Million USD	-57.52%
2021 Q4	11.17 Million USD	-60.81%
2021 Q2	67.11 Million USD	46.21%
2021 Q1	45.9 Million USD	127.51%
2021 FY	209.23 Million USD	129.54%
2020 Q2	10.75 Million USD	-81.4%
2020 Q4	20.17 Million USD	728.67%
2020 FY	91.15 Million USD	166.33%
2020 Q3	2.43 Million USD	-77.35%
2020 Q1	57.79 Million USD	349.8%
2019 Q2	-18.91 Million USD	79.96%
2019 Q4	-23.13 Million USD	79.39%
2019 FY	-137.42 Million USD	-598.54%
2019 Q1	-94.36 Million USD	-505.33%
2019 Q3	-112.27 Million USD	-493.63%
2018 Q2	-181.06 Million USD	-384.89%
2018 FY	-19.67 Million USD	-108.03%
2018 Q4	23.28 Million USD	-68.77%
2018 Q3	74.55 Million USD	141.18%
2018 Q1	63.55 Million USD	-19.57%
2017 FY	245.1 Million USD	-13.96%
2017 Q1	42.72 Million USD	-53.71%
2017 Q2	44.6 Million USD	4.39%
2017 Q3	78.75 Million USD	76.56%
2017 Q4	79.01 Million USD	0.34%
2016 Q4	92.29 Million USD	0.0%
2016 FY	284.88 Million USD	25.37%
2015 FY	227.23 Million USD	1.92%
2014 FY	222.94 Million USD	0.0%

Peer Operating Income Comparison of Amneal Pharmaceuticals, Inc.

Name	Operating Income	Operating Income Difference
Bausch Health Companies Inc.	963 Million USD	78.777%
Catalent, Inc.	-749 Million USD	127.286%
Emergent BioSolutions Inc.	-726.4 Million USD	128.135%
Elanco Animal Health Incorporated	326 Million USD	37.309%
Perrigo Company plc	151.9 Million USD	-34.545%
Teva Pharmaceutical Industries Limited	433 Million USD	52.8%
Zoetis Inc.	3.06 Billion USD	93.341%